ArticleCureus2022
Factors Associated With Visual Acuity in Non-arteritic Ischemic Optic Neuropathy Patients: A Five-Year Cross-Sectional Study.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 3 citations in OpenAlex.
- Risk factor profiles and visual outcomes of non-arteritic anterior ischemic optic neuropathy in younger Chinese patients.BMC ophthalmology · 2026Article
- Development of a predictive model for visual outcomes and risk factors of bilateral involvement for non-arteritic anterior ischemic optic neuropathy (NAION) in Chinese patients.Eye and vision (London, England) · 2026Article
- Vision-Related Quality of Life in Patients with Optic Neuropathy: Insights from a Portuguese Single Center Using the NEI-VFQ-25.Neurology international · 2025Article
- Risk factors of developing non-arteric ischemic optic neuropathy in patients with type 2 diabetes mellitus: a single-center retrospective cohort study.International journal of ophthalmology · 2025Article
- Peripapillary Retinal Nerve Fiber Layer Thickness as a Predictor of Visual Outcomes in Patients with Acute Nonarteritic Anterior Ischemic Optic Neuropathy.Clinical ophthalmology (Auckland, N.Z.) · 2024Article
- Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION): A Comprehensive Overview.Vision (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective Non-arteritic ischemic optic neuropathy (NAION) is a common cause of optic neuropathy in elderly patients. Currently, there is no definitive treatment for this condition, and the factors influencing visual outcomes have not yet been conclusively identified. In this study, we aimed to evaluate factors that affect visual outcomes and those that are predictors of the development of NAION in a Thai population. Methods All patients diagnosed with NAION at the Rajavithi Hospital between January 1, 2016, and December 31, 2020, were retrospectively reviewed to evaluate the improvement in their best-corrected visual acuity (BCVA) and determine the factors that are predictive of visual outcomes. Results The 80 patients reviewed were predominantly male (55%) with a mean age of 55.8 ±9.89 years. Their most common comorbidities were dyslipidemia (DLP) (67.5%), diabetes mellitus (DM) (61.3%), and hypertension (HT) (48.8%). At the 12-week follow-up visit, there was a significant improvement of at least 0.2 logarithm of the minimum angle of resolution (logMAR) in BCVA (p=0.001). A significantly greater percentage of patients with higher age, DM, and HT was observed in the unfavorable visual recovery (UVR) group (p=0.002, p=0.001, and p=0.005 respectively). In contrast, neither baseline visual acuity nor cup-to-disc ratio (CDR) affected the result of visual recovery (p=0.275 and p=0.076, respectively). In multivariate logistic analysis, older age increased the odds of worse visual recovery [odds ratio (OR): 4.014; 95% CI: 1.038-15.515; p=0.044], as did having DM (OR: 3.809; 95% CI: 1.168-12.421; p=0.027), and HT (OR: 4.577; 95% CI: 1.491-14.049; p=0.008). Conclusions None of the baseline visual status parameters (visual acuity, CDR, or visual field defect) was able to determine the outcome of visual recovery at 12 weeks in our NAION patients. Regarding systemic vascular diseases, diabetes and HT are significant risk factors and also predictors of poor visual improvement in Thai populations. NAION patients who are elderly or have vascular diseases such as DM or HT should be closely followed up and advised about the likelihood of having inferior visual recovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.